Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs REP 2139-Ca (Primary) ; Entecavir; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors REPLICor
- 06 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2016 According to a Replicor media release, updated clinical data of this study will be presented at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver.
- 10 Apr 2015 According to a REPLICor media release, the updated data from this and another trial will be presented at the 2015 Lancet Viral Hepatitis Conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History